Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China

BACKGROUND: Toripalimab is the first domestic anti-tumor programmed death 1 antibody marketed in China. The CHOICE-01 trial (identifier: NCT 03856411) demonstrated that toripalimab plus chemotherapy can significantly improve the clinical outcomes of advanced non-small cell lung cancer (NSCLC) patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Mengdie, Xu, Kai, Lin, Yingtao, Zhou, Chongchong, Bao, Yuwen, Zhang, Lingli, Li, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258326/
https://www.ncbi.nlm.nih.gov/pubmed/37313403
http://dx.doi.org/10.3389/fimmu.2023.1169752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258326/
https://www.ncbi.nlm.nih.gov/pubmed/37313403
http://dx.doi.org/10.3389/fimmu.2023.1169752

Ejemplares similares